Kamada and Chiesi Enter into a Strategic Agreement for the Distribution of Kamada's Inhaled AAT Drug for Treatment of Alpha-1 Antitrypsin Deficiency in Europe, Turkey and Former CIS Countries
08:00 EDT 6 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Kamada, Ltd. (TASE: KMDA), a biopharmaceutical company engaged in
development, manufacturing and marketing of specialty life-saving
therapeutics announced today it has entered into an exclusive
distribution agreement with Chiesi...
Other Sources for this Article
Kamada, Ltd.
Gil Efron, CFO
+972-8-9913170
GilE@kamada.com
More From BioPortfolio on "Kamada and Chiesi Enter into a Strategic Agreement for the Distribution of Kamada's Inhaled AAT Drug for Treatment of Alpha-1 Antitrypsin Deficiency in Europe, Turkey and Former CIS Countries"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
